What's Happening?
Thermo Fisher Scientific has inaugurated its East Coast Advanced Therapies Collaboration Center (ATxCC) in Philadelphia, marking its second such facility in the United States. This new center aims to support the development of cell and gene therapies by providing biotech startups and biopharma organizations with access to Thermo Fisher's expert scientists and advanced process development technologies. The Philadelphia ATxCC is located within BioLabs for Advanced Therapeutics, a 53,000-square-foot biotech incubator, offering collaboration opportunities to researchers focused on next-generation cell-based immunotherapies. The center is part of Thermo Fisher's strategy to expand its network and facilitate the transition of advanced therapies from
research to clinical readiness.
Why It's Important?
The opening of the Philadelphia ATxCC is significant as it addresses the growing demand for scalable solutions in the development of advanced therapies, which have the potential to treat diseases previously considered untreatable. By providing critical resources and collaboration opportunities, Thermo Fisher is enabling biotech and biopharma organizations to overcome hurdles in therapy development, ultimately accelerating the delivery of transformative treatments to patients. This initiative reflects the company's commitment to advancing healthcare and supporting innovation in the field of cell and gene therapy.
What's Next?
The Philadelphia ATxCC is expected to play a crucial role in supporting startups and biopharma organizations as they progress from laboratory research to clinical applications. The center will likely foster collaborations that could lead to breakthroughs in cell and gene therapy, potentially attracting more investment and interest in the region's biotech sector. As demand for advanced therapies continues to grow, Thermo Fisher's network expansion may lead to further openings of similar centers across the United States.
